JP2018533954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533954A5 JP2018533954A5 JP2018524194A JP2018524194A JP2018533954A5 JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5 JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- expression
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229920000272 Oligonucleotide Polymers 0.000 claims 5
- 102100007198 UBE3A Human genes 0.000 claims 3
- 101700027248 UBE3A Proteins 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 208000009575 Angelman Syndrome Diseases 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 229920001168 Small nucleolar RNA SNORD115 Polymers 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003867 nerve cell Anatomy 0.000 claims 1
- 210000002569 neurons Anatomy 0.000 claims 1
- 159000000001 potassium salts Chemical group 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Claims (12)
- オリゴヌクレオチドが、オリゴヌクレオチド化合物TTAcActtaattatactTCC(化合物識別番号626_7)であり、ここで大文字がβ−D−オキシLNAヌクレオシドを表し、小文字がDNAヌクレオシドを表し、すべてのLNAのCが5−メチルシトシンであり、そしてすべてのヌクレオシド間結合がホスホロチオエート・ヌクレオシド間結合である、アンチセンスオリゴヌクレオチド。
- 請求項1に記載のオリゴヌクレオチドならびに、医薬的に許容される希釈剤、溶媒、担体、塩、および/または補助剤を含む、医薬組成物。
- 前記医薬として許容される希釈剤が、リン酸緩衝生理食塩水(PBS)を含む、請求項2に記載の医薬組成物。
- 前記医薬として許容される塩が、ナトリウム塩である、請求項2又は3に記載の医薬組成物。
- 前記医薬として許容される塩が、カリウム塩である、請求項2又は3に記載の医薬組成物。
- 医薬として使用するための、請求項2〜5のいずれか一項に記載の医薬組成物。
- 父方UBE3Aの発現が抑制されている標的細胞におけるUBE3A発現を生体外で導入する方法であって、
前記細胞に、請求項1に記載のオリゴヌクレオチドまたは請求項2〜5のいずれか一項に記載の医薬組成物の有効量を投与すること
を含む方法。 - 前記UBE3Aの発現が対照に比べて少なくとも40%増加している、請求項7に記載の方法。
- SNORD109Bの下流のSNHG14転写物の水準が対照に比べて少なくとも30%減少している、請求項7または8に記載の方法。
- 前記標的細胞は神経細胞である、請求項7〜9のいずれか1項に記載の方法。
- 前記SNORD115の発現は対照に比べて有意の影響を受けていない、請求項7〜10のいずれか1項に記載の方法。
- アンジェルマン症候群の治療または予防のための請求項2〜5のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15194367.7 | 2015-11-12 | ||
EP15194367 | 2015-11-12 | ||
EP16189502.4 | 2016-09-19 | ||
EP16189502 | 2016-09-19 | ||
PCT/EP2016/077383 WO2017081223A1 (en) | 2015-11-12 | 2016-11-11 | Oligonucleotides for inducing paternal ube3a expression |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020136397A Division JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ube3aの発現を誘導するオリゴヌクレオチド |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018533954A JP2018533954A (ja) | 2018-11-22 |
JP2018533954A5 true JP2018533954A5 (ja) | 2020-04-09 |
JP6751142B2 JP6751142B2 (ja) | 2020-09-02 |
Family
ID=57345910
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018521350A Pending JP2018533362A (ja) | 2015-11-12 | 2016-11-11 | 薬物候補の有効性プロファイルを決定するための方法 |
JP2018521433A Active JP7066609B2 (ja) | 2015-11-12 | 2016-11-11 | 霊長類種に由来する標準化された神経細胞アッセイ |
JP2018524194A Active JP6751142B2 (ja) | 2015-11-12 | 2016-11-11 | 父方ube3aの発現を誘導するオリゴヌクレオチド |
JP2020136397A Active JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ube3aの発現を誘導するオリゴヌクレオチド |
JP2021113496A Pending JP2021191262A (ja) | 2015-11-12 | 2021-07-08 | 薬物候補の有効性プロファイルを決定するための方法 |
JP2023009553A Pending JP2023052630A (ja) | 2015-11-12 | 2023-01-25 | 父方ube3aの発現を誘導するオリゴヌクレオチド |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018521350A Pending JP2018533362A (ja) | 2015-11-12 | 2016-11-11 | 薬物候補の有効性プロファイルを決定するための方法 |
JP2018521433A Active JP7066609B2 (ja) | 2015-11-12 | 2016-11-11 | 霊長類種に由来する標準化された神経細胞アッセイ |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020136397A Active JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ube3aの発現を誘導するオリゴヌクレオチド |
JP2021113496A Pending JP2021191262A (ja) | 2015-11-12 | 2021-07-08 | 薬物候補の有効性プロファイルを決定するための方法 |
JP2023009553A Pending JP2023052630A (ja) | 2015-11-12 | 2023-01-25 | 父方ube3aの発現を誘導するオリゴヌクレオチド |
Country Status (30)
Country | Link |
---|---|
US (9) | US10494633B2 (ja) |
EP (5) | EP3374509B1 (ja) |
JP (6) | JP2018533362A (ja) |
KR (3) | KR102482440B1 (ja) |
CN (5) | CN108291226B (ja) |
AU (3) | AU2016352836B2 (ja) |
BR (1) | BR112018007633A2 (ja) |
CA (1) | CA3004799C (ja) |
CL (3) | CL2018001189A1 (ja) |
CO (1) | CO2018004550A2 (ja) |
CR (3) | CR20220077A (ja) |
DK (1) | DK3374509T3 (ja) |
ES (1) | ES2852998T4 (ja) |
HK (3) | HK1253325A1 (ja) |
HR (1) | HRP20210227T1 (ja) |
HU (1) | HUE053197T2 (ja) |
IL (3) | IL281211B2 (ja) |
LT (1) | LT3374509T (ja) |
MX (4) | MX2018004978A (ja) |
NZ (1) | NZ741585A (ja) |
PE (2) | PE20210451A1 (ja) |
PH (1) | PH12018501005A1 (ja) |
PL (1) | PL3374509T3 (ja) |
RS (1) | RS61529B9 (ja) |
RU (1) | RU2742007C2 (ja) |
SG (1) | SG11201803951QA (ja) |
SI (1) | SI3374509T1 (ja) |
UA (1) | UA125963C2 (ja) |
WO (3) | WO2017081250A1 (ja) |
ZA (1) | ZA201802494B (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
KR101885383B1 (ko) | 2009-07-06 | 2018-08-03 | 웨이브 라이프 사이언시스 리미티드 | 신규한 핵산 프로드러그 및 그의 사용 방법 |
JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
EP4219516A3 (en) | 2012-07-13 | 2024-01-10 | Wave Life Sciences Ltd. | Chiral control |
WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
KR102423317B1 (ko) | 2014-01-16 | 2022-07-22 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
WO2016086104A1 (en) | 2014-11-25 | 2016-06-02 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
PE20210451A1 (es) | 2015-11-12 | 2021-03-08 | Hoffmann La Roche | Oligonucleotidos para inducir la expresion paterna de ube3a |
JP7297320B2 (ja) * | 2017-12-01 | 2023-06-26 | ザ テキサス エイ・アンド・エム ユニヴァーシティ システム | アンジェルマン症候群アンチセンス治療 |
EP3752612A4 (en) | 2018-02-12 | 2021-11-10 | Ionis Pharmaceuticals, Inc. | MODIFIED COMPOUNDS AND USES THEREOF |
CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
US20210332368A1 (en) * | 2018-09-21 | 2021-10-28 | University Of Connecticut | Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome |
WO2020148310A1 (en) | 2019-01-17 | 2020-07-23 | F. Hoffmann-La Roche Ag | E3 ubiquitin ligase (ube3a) protein targets |
JOP20210261A1 (ar) * | 2019-03-29 | 2023-01-30 | Ionis Pharmaceuticals Inc | مركبات وطرق لتعديل ube3a-ats |
CA3139678A1 (en) * | 2019-05-22 | 2020-11-26 | The University Of North Carolina At Chapel Hill | Ube3a genes and expression cassettes and their use |
WO2020239714A1 (en) | 2019-05-28 | 2020-12-03 | F. Hoffmann-La Roche Ag | Method to generate monocytic progenitor cells |
EP4162047A1 (en) * | 2020-06-09 | 2023-04-12 | Roche Innovation Center Copenhagen A/S | Guanosine analogues for use in therapeutic polynucleotides |
EP4282651A1 (en) | 2021-01-21 | 2023-11-29 | Fujimori Kogyo Co., Ltd. | Layered film and packaging bag |
WO2023217890A1 (en) | 2022-05-10 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting cfp-elk1 intergene region |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4373084A (en) | 1981-07-07 | 1983-02-08 | E. I. Du Pont De Nemours And Company | Sulfur-modified polypropylene ether glycols, a method for preparing them, and polyurethanes prepared therefrom |
JP2823959B2 (ja) | 1991-10-24 | 1998-11-11 | アイシス・ファーマシューティカルス・インコーポレーテッド | 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6617162B2 (en) | 2001-12-18 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of estrogen receptor alpha expression |
NZ503765A (en) | 1997-09-12 | 2002-04-26 | Exiqon As | Bi-cyclic and tri-cyclic nucleotide analogues |
US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
WO2000040749A2 (en) * | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
ID30093A (id) | 1999-02-12 | 2001-11-01 | Sankyo Co | Analog-analog nukleosida dan oligonukleotida baru |
JP2002543214A (ja) | 1999-05-04 | 2002-12-17 | エクシコン エ/エス | L−リボ−lna類縁体 |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
CA2396460A1 (en) | 1999-12-02 | 2001-06-07 | Myriad Genetics, Inc. | Protein-protein interactions |
US6300132B1 (en) | 1999-12-17 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Antisense inhibition of telomeric repeat binding factor 2 expression |
AU2001268163A1 (en) * | 2000-06-01 | 2001-12-11 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ube3a gene |
US20030087855A1 (en) | 2001-09-13 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of protein kinase R expression |
AU2002315393A1 (en) * | 2001-06-21 | 2003-01-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
US20050124572A1 (en) * | 2002-06-17 | 2005-06-09 | Freier Susan M. | Compositions and their uses directed to signal tranducers |
WO2004016754A2 (en) | 2002-08-14 | 2004-02-26 | Pharmacia Corporation | ANTISENSE MODULATION OF Nav1.3 EXPRESSION |
EP1575498A2 (en) * | 2002-09-25 | 2005-09-21 | Pharmacia Corporation | Antisense modulation of microsomal prostaglandin e2 synthase expression |
DK2752488T3 (da) | 2002-11-18 | 2020-04-20 | Roche Innovation Ct Copenhagen As | Antisense-design |
KR20060115351A (ko) | 2003-08-29 | 2006-11-08 | 위스콘신 얼럼나이 리서어치 화운데이션 | 영장류 배아 줄기 세포 기원의 신경 줄기 세포, 운동 뉴런및 도파민 뉴런의 시험관내 분화 방법 |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
CA2640171C (en) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
ES2471978T3 (es) | 2006-05-05 | 2014-06-27 | Isis Pharmaceuticals, Inc. | Compuestos y procedimientos para modular la expresión de ApoB |
WO2007134181A2 (en) | 2006-05-11 | 2007-11-22 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
PE20090064A1 (es) | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
DK2285819T3 (da) | 2008-04-04 | 2013-12-02 | Isis Pharmaceuticals Inc | Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider |
DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
US8642334B2 (en) * | 2009-02-17 | 2014-02-04 | Memorial Sloan Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
WO2011017521A2 (en) | 2009-08-06 | 2011-02-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
CN102762718B (zh) | 2009-10-13 | 2015-06-17 | 干细胞技术公司 | 用于分化干细胞的重量克分子渗透压浓度控制 |
EP2516648B1 (en) | 2009-12-23 | 2017-11-08 | CuRNA, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
EP2593547B1 (en) | 2010-07-14 | 2017-11-15 | CuRNA, Inc. | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
EP2595664B1 (en) | 2010-07-19 | 2018-10-17 | Ionis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
EP2606126B1 (en) * | 2010-08-19 | 2016-05-18 | F.Hoffmann-La Roche Ag | Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs) |
US9714427B2 (en) | 2010-11-11 | 2017-07-25 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
WO2012068405A2 (en) | 2010-11-17 | 2012-05-24 | Isis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
US9487752B2 (en) | 2011-03-30 | 2016-11-08 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
AU2012244816B2 (en) | 2011-04-20 | 2015-12-10 | Roche Glycart Ag | Method and constructs for the pH dependent passage of the blood-brain-barrier |
EP2751270B1 (en) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
WO2013036868A1 (en) | 2011-09-07 | 2013-03-14 | Marina Biotech Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
ES2809199T3 (es) | 2012-06-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | Modulación de la expresión de UBE3A-ATS |
PL2920304T3 (pl) | 2012-11-15 | 2019-07-31 | Roche Innovation Center Copenhagen A/S | Koniugaty oligonukleotydowe |
WO2014077693A1 (en) | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
WO2015143342A1 (en) * | 2014-03-21 | 2015-09-24 | Cellular Dynamics International, Inc. | Production of midbrain dopaminergic neurons and methods for the use thereof |
PE20210451A1 (es) | 2015-11-12 | 2021-03-08 | Hoffmann La Roche | Oligonucleotidos para inducir la expresion paterna de ube3a |
WO2019006107A1 (en) | 2017-06-28 | 2019-01-03 | University Of South Florida | MODIFIED UBE3A GENE FOR GENE THERAPY APPROACH TO ANGELMAN'S SYNDROME |
JP7297320B2 (ja) | 2017-12-01 | 2023-06-26 | ザ テキサス エイ・アンド・エム ユニヴァーシティ システム | アンジェルマン症候群アンチセンス治療 |
AU2019212849B2 (en) | 2018-01-26 | 2024-02-29 | F. Hoffmann-La Roche Ag | Radiolabelled oligonucleotides and process for their preparation |
JOP20210261A1 (ar) | 2019-03-29 | 2023-01-30 | Ionis Pharmaceuticals Inc | مركبات وطرق لتعديل ube3a-ats |
-
2016
- 2016-11-11 PE PE2020000810A patent/PE20210451A1/es unknown
- 2016-11-11 KR KR1020207033999A patent/KR102482440B1/ko not_active Application Discontinuation
- 2016-11-11 CR CR20220077A patent/CR20220077A/es unknown
- 2016-11-11 PL PL16798440T patent/PL3374509T3/pl unknown
- 2016-11-11 EP EP16798440.0A patent/EP3374509B1/en active Active
- 2016-11-11 CN CN201680066253.6A patent/CN108291226B/zh active Active
- 2016-11-11 MX MX2018004978A patent/MX2018004978A/es unknown
- 2016-11-11 DK DK16798440.0T patent/DK3374509T3/da active
- 2016-11-11 EP EP20204481.4A patent/EP3798307A1/en active Pending
- 2016-11-11 IL IL281211A patent/IL281211B2/en unknown
- 2016-11-11 RS RS20210241A patent/RS61529B9/sr unknown
- 2016-11-11 CN CN201680066009.XA patent/CN108350432A/zh active Pending
- 2016-11-11 EP EP16797824.6A patent/EP3374498A1/en active Pending
- 2016-11-11 JP JP2018521350A patent/JP2018533362A/ja active Pending
- 2016-11-11 ES ES16798440T patent/ES2852998T4/es active Active
- 2016-11-11 PE PE2018000752A patent/PE20181157A1/es unknown
- 2016-11-11 CN CN202211275978.XA patent/CN116064540A/zh active Pending
- 2016-11-11 LT LTEP16798440.0T patent/LT3374509T/lt unknown
- 2016-11-11 WO PCT/EP2016/077429 patent/WO2017081250A1/en active Application Filing
- 2016-11-11 JP JP2018521433A patent/JP7066609B2/ja active Active
- 2016-11-11 KR KR1020227045154A patent/KR20230008233A/ko not_active Application Discontinuation
- 2016-11-11 SI SI201631093T patent/SI3374509T1/sl unknown
- 2016-11-11 CN CN201680065987.2A patent/CN108350431A/zh active Pending
- 2016-11-11 AU AU2016352836A patent/AU2016352836B2/en active Active
- 2016-11-11 CR CR20180264A patent/CR20180264A/es unknown
- 2016-11-11 HU HUE16798440A patent/HUE053197T2/hu unknown
- 2016-11-11 CA CA3004799A patent/CA3004799C/en active Active
- 2016-11-11 CN CN202211275954.4A patent/CN116064539A/zh active Pending
- 2016-11-11 EP EP23152543.7A patent/EP4220360A3/en active Pending
- 2016-11-11 RU RU2018119315A patent/RU2742007C2/ru active
- 2016-11-11 WO PCT/EP2016/077383 patent/WO2017081223A1/en active Application Filing
- 2016-11-11 CR CR20200118A patent/CR20200118A/es unknown
- 2016-11-11 KR KR1020187013292A patent/KR102185465B1/ko active IP Right Grant
- 2016-11-11 NZ NZ741585A patent/NZ741585A/en unknown
- 2016-11-11 SG SG11201803951QA patent/SG11201803951QA/en unknown
- 2016-11-11 WO PCT/EP2016/077435 patent/WO2017081254A1/en active Application Filing
- 2016-11-11 EP EP16798672.8A patent/EP3374499A1/en active Pending
- 2016-11-11 UA UAA201806476A patent/UA125963C2/uk unknown
- 2016-11-11 BR BR112018007633-3A patent/BR112018007633A2/pt active Search and Examination
- 2016-11-11 IL IL300119A patent/IL300119A/en unknown
- 2016-11-11 JP JP2018524194A patent/JP6751142B2/ja active Active
- 2016-11-14 US US15/351,113 patent/US10494633B2/en active Active
-
2018
- 2018-04-03 IL IL258488A patent/IL258488B/en active IP Right Grant
- 2018-04-16 ZA ZA2018/02494A patent/ZA201802494B/en unknown
- 2018-04-23 MX MX2022016377A patent/MX2022016377A/es unknown
- 2018-04-23 MX MX2022016376A patent/MX2022016376A/es unknown
- 2018-04-23 MX MX2022016381A patent/MX2022016381A/es unknown
- 2018-04-26 CO CONC2018/0004550A patent/CO2018004550A2/es unknown
- 2018-05-03 CL CL2018001189A patent/CL2018001189A1/es unknown
- 2018-05-08 PH PH12018501005A patent/PH12018501005A1/en unknown
- 2018-05-11 US US15/977,895 patent/US20190144824A1/en active Pending
- 2018-05-11 US US15/977,970 patent/US20190154664A1/en active Pending
- 2018-10-02 HK HK18112618.7A patent/HK1253325A1/zh unknown
-
2019
- 2019-01-15 HK HK19100670.6A patent/HK1258434A1/zh unknown
- 2019-01-15 HK HK19100676.0A patent/HK1258309A1/zh unknown
- 2019-04-18 US US16/388,714 patent/US10739332B2/en active Active
- 2019-10-24 US US16/663,024 patent/US10718753B2/en active Active
-
2020
- 2020-04-02 CL CL2020000889A patent/CL2020000889A1/es unknown
- 2020-05-29 AU AU2020203573A patent/AU2020203573B2/en active Active
- 2020-07-20 US US16/933,445 patent/US11320421B2/en active Active
- 2020-08-12 JP JP2020136397A patent/JP7279000B2/ja active Active
-
2021
- 2021-02-09 HR HRP20210227TT patent/HRP20210227T1/hr unknown
- 2021-07-08 JP JP2021113496A patent/JP2021191262A/ja active Pending
- 2021-08-13 CL CL2021002159A patent/CL2021002159A1/es unknown
-
2022
- 2022-01-21 US US17/581,089 patent/US11852627B2/en active Active
-
2023
- 2023-01-25 JP JP2023009553A patent/JP2023052630A/ja active Pending
- 2023-01-25 AU AU2023200410A patent/AU2023200410A1/en active Pending
- 2023-02-22 US US18/172,707 patent/US20230296587A1/en active Pending
- 2023-10-20 US US18/491,513 patent/US20240085402A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018533954A5 (ja) | ||
HRP20210227T1 (hr) | Oligonukleotidi za indukciju ekspresije paternalnog gena ube3a | |
MX2019005816A (es) | Agentes de arn modificados con efecto reducido fuera de la diana. | |
WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
SG10201903290YA (en) | Modified double-stranded rna agents | |
JP2018523668A5 (ja) | ||
JP2018519835A5 (ja) | ||
BR112019002117A2 (pt) | agente de rnai contra infecção do vírus da hepatite b | |
MX2018012038A (es) | Agentes de iarn modificados. | |
WO2014022739A3 (en) | Modified rnai agents | |
BR112013010525A2 (pt) | tratamento de hbv | |
JP2016522674A5 (ja) | ||
JP2018529732A5 (ja) | ||
RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
JP2015516989A5 (ja) | ||
WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
JP2016533717A5 (ja) | ||
BR112015021470A2 (pt) | conjugado de polímero para administração de um agente bioativo | |
JP2015518710A5 (ja) | ||
CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
WO2019217397A3 (en) | Compositions and methods for improving strand biased | |
BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
BR112022004424A2 (pt) | Pró-fármacos antivirais e formulações dos mesmos | |
RU2019101298A (ru) | Антисмысловые олигонуклеотиды для модулирования экспрессии htra1 | |
AU2016229966A8 (en) | Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |